Bristol Myers Squibb Total Liabilities 2010-2022 | BMY

Bristol Myers Squibb total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Bristol Myers Squibb total liabilities for the quarter ending March 31, 2022 were $71.389B, a 4.51% decline year-over-year.
  • Bristol Myers Squibb total liabilities for 2021 were $73.308B, a 9.05% decline from 2020.
  • Bristol Myers Squibb total liabilities for 2020 were $80.599B, a 3.01% increase from 2019.
  • Bristol Myers Squibb total liabilities for 2019 were $78.246B, a 275.12% increase from 2018.
Bristol Myers Squibb Annual Total Liabilities
(Millions of US $)
2021 $73,308
2020 $80,599
2019 $78,246
2018 $20,859
2017 $21,704
2016 $17,360
2015 $17,324
2014 $18,766
2013 $23,356
2012 $22,259
2011 $17,103
2010 $15,438
2009 $16,223
Bristol Myers Squibb Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $71,389
2021-12-31 $73,308
2021-09-30 $73,609
2021-06-30 $73,923
2021-03-31 $74,762
2020-12-31 $80,599
2020-09-30 $75,306
2020-06-30 $78,916
2020-03-31 $79,308
2019-12-31 $78,246
2019-09-30 $39,679
2019-06-30 $39,012
2019-03-31 $19,517
2018-12-31 $20,859
2018-09-30 $19,984
2018-06-30 $20,223
2018-03-31 $20,177
2017-12-31 $21,704
2017-09-30 $19,063
2017-06-30 $18,588
2017-03-31 $18,402
2016-12-31 $17,360
2016-09-30 $17,946
2016-06-30 $17,753
2016-03-31 $17,341
2015-12-31 $17,324
2015-09-30 $16,506
2015-06-30 $16,663
2015-03-31 $17,890
2014-12-31 $18,766
2014-09-30 $18,249
2014-06-30 $18,124
2014-03-31 $17,893
2013-12-31 $23,356
2013-09-30 $22,090
2013-06-30 $21,879
2013-03-31 $22,259
2012-12-31 $22,259
2012-09-30 $22,144
2012-06-30 $15,855
2012-03-31 $16,162
2011-12-31 $17,103
2011-09-30 $15,578
2011-06-30 $15,688
2011-03-31 $14,950
2010-12-31 $15,438
2010-09-30 $16,028
2010-06-30 $15,477
2010-03-31 $15,520
2009-12-31 $16,223
2009-09-30 $16,580
2009-06-30 $15,873
2009-03-31 $16,564
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $163.597B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00